IGSF8: A Potential Drug Target Or Biomarker (G93185)

Target Name: IGSF8

NCBI ID: G93185

IGSF8

IGSF8: A Potential Drug Target Or Biomarker

IGSF8 (Immunoglobulin Light Chain Fragments 8) is a protein that is expressed in a variety of tissues throughout the body, including the blood, bones, and organs. It is a component of the humoral immune system, which is responsible for the production and response to antibodies. IGSF8 is one of several proteins that are known as immune globulin light chains, which play an important role in the immune system. However, recent studies suggest that IGSF8 may also be a potential drug target or biomarker.

The role of IGSF8 in the immune system and its relationship to disease have been extensively studied. As an immunoglobulin light chain, the main role of IGSF8 is to participate in the recognition and response of immune cells. It can bind to other immunoglobulins, thereby activating a range of immune cells, such as B cells and T cells. After activation, IGSF8 releases a variety of biologically active substances, such as cytokines and growth factors, which can promote the growth and activation of immune cells. In addition, IGSF8 can also bind to tumor cells and promote their growth and spread. These findings provide an important theoretical basis for IGSF8 as a drug target or biomarker.

In addition to its role in the immune system, IGSF8 is also closely related to the occurrence and development of disease. For example, some studies have shown that the expression level of IGSF8 can reflect the health of a person's immune system. In certain diseases, such as multiple myeloma and systemic interstitial macrocytic anemia, elevated IGSF8 can be used as a predictor of disease progression. In addition, IGSF8 is also closely related to the occurrence and development of some diseases, such as osteoarthritis and Alzheimer's disease. These findings provide important clinical implications for IGSF8 as a drug target or biomarker.

Although current research on IGSF8 mainly focuses on its role in the immune system and its relationship with disease, studies have shown that it may also have other potential roles. For example, some studies have shown that IGSF8 can interfere with the growth and apoptosis of neurons, which may be related to neurological diseases. In addition, IGSF8 can also regulate the metabolism of immune cells, which may be related to metabolic diseases.

In summary, IGSF8, as an immunoglobulin light chain, has been extensively studied for its role in the immune system and its relationship with diseases. In addition to its role in the immune system, IGSF8 is also closely related to the occurrence and development of disease. Therefore, NGSF8 may be a potential drug target or biomarker with good clinical prospects.

Protein Name: Immunoglobulin Superfamily Member 8

Functions: May play a key role in diverse functions ascribed to CD81 and CD9 such as oocytes fertilization or hepatitis C virus function. May regulate proliferation and differentiation of keratinocytes. May be a negative regulator of cell motility: suppresses T-cell mobility coordinately with CD81, associates with CD82 to suppress prostate cancer cell migration, regulates epidermoid cell reaggregation and motility on laminin-5 with CD9 and CD81 as key linkers. May also play a role on integrin-dependent morphology and motility functions. May participate in the regulation of neurite outgrowth and maintenance of the neural network in the adult brain

The "IGSF8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGSF8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets